CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. As part of the restructure, CSL Seqirus will be demerged in order to list as an independent company on the Australian Stock Exchange by the end of the next Australian financial year, which ends June 30, 2026. Source: Fierce Biotech 19/8/2025